Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2319 - P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer


09 Sep 2017


Poster display session


Clinical Research;  Immunotherapy;  Anal Cancer


Cathy Eng


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


C. Eng1, M. Fakih2, M. Amin3, V. Morris1, H.S. Hochster4, P.M. Boland5, H. Uronis6

Author affiliations

  • 1 Department Of Gastrointestinal (gi) Medical Oncology, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 Medical Oncology, City of Hope, 91010 - Duarte/US
  • 3 Medical Oncology, Siteman Cancer Center, Washington University School of Medicine, 63110 - St. Louis/US
  • 4 Yale University, Yale Cancer Center, New Haven/US
  • 5 Medical Oncology, Roswell Park Cancer Institute, Buffalo/US
  • 6 Medical Oncology, Duke Cancer Institute, 27710 - Durham/US


Abstract 2319


The number of new anal cancer (SCCA) cases in the US has been rising annually; 20% of patients (pts) will develop metastatic (met) disease, which presents an unmet medical need. A large population-based study showed 88% of SCCA were HPV+ and 73% had HPV-16 (Hoots et al IJC 2009). ADXS11-001 (ADXS) is an irreversibly attenuated Listeria monocytogenes immunotherapy that targets HPV-associated cancers. It is bioengineered to secrete an antigen-adjuvant protein fused to the E7 peptide of HPV-16. It allows the generation of tumor antigen specific cytotoxic T cells that infiltrate and destroy tumor cells. This is the 1st P2 trial to assess the efficacy/safety of ADXS in met SCCA.


This multicenter, open-label, 2-stage design trial (NCT02399813) includes pts ≥ 18 yrs with histologically confirmed, measurable SCCA and previous ≥ 1 line of therapy for advanced disease. Pts received IV ADXS monotherapy (1x109 colony forming units) every 3 weeks for ≤ 2 years or until a discontinuation criterion was met. Tumor assessments (RECIST 1.1) were every 9 wks. Interim analysis was planned on enrollment of 31 evaluable pts (≥ 1 post-baseline scan). An objective response rate (ORR) ≥ 10% or a 6-month progression free survival (PFS) ≥ 20% with tolerable safety would allow proceeding to Stage 2.


Preliminary Stage 1 results are reported with data from 29 of the planned 31 evaluable pts. Median age 60 yrs, range 43-77; 27 F/2 M; median follow-up time 191 days. One pt (3.5%) had a durable partial response lasting > 6 months (after progression on prior anti-PD-1 therapy) and 7 pts had stable disease (24%). Disease control rate was 28%. The current KM 6-month PFS estimate is 22%. Common (≥ 30%) treatment related AEs (TRAEs) were grade 1-2 chills/rigors, fever, hypotension and vomiting. Grade 3 TRAEs of cytokine related syndrome (n = 1; SAE), infusion related reactions (n = 2; 1 SAE) and hypotension (n = 2; 1 SAE) were reported.


ADXS monotherapy showed promising activity and met the predefined 6-month PFS rate. Treatment was well-tolerated with mostly grade 1-2 infusion related AEs that resolved successfully with standard care. Further investigation is ongoing in this population.

Clinical trial identification


Legal entity responsible for the study

Advaxis, Inc


Advaxis, Inc


C. Eng: Consulting agreement with Advaxis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.